X0206 3 2022-06-13 0 0001579428 Axsome Therapeutics, Inc. AXSM 0001934008 Murdock Hunter R. C/O AXSOME THERAPEUTICS, INC. 22 CORTLANDT ST, 16TH FLOOR NEW YORK NY 10007 0 1 0 0 General Counsel Stock Option (Right to Buy) 32.55 2031-12-13 Common Stock 40000 D Stock Option (Right to Buy) 29.91 2032-03-04 Common Stock 52383 D Restricted Stock Units Common Stock 22254 D Restricted Stock Units Common Stock 27698 D The option was granted on December 13, 2021. 25% of the option vests on the one (1) year anniversary of the date of grant with the remaining 75% to vest in equal increments on a quarterly basis over a four (4) year period, until fully vested. The option was granted on March 4, 2022, and vests in equal increments on a quarterly basis over a four (4) year period, until fully vested. The restricted stock units ("RSUs") were granted on December 13, 2021. 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on December 13, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan")), (ii) separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability) of the reporting person or (iii) seven (7) years from the date of grant. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 4, 2022. 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Plan), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. /s/ Hunter Murdock 2022-06-15